as of 09-04-2026 11:12am EST
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.7M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -326.74 | EPS Growth: | -7179.59 |
| 52 Week Low/High: | $0.05 - $28.32 | Next Earning Date: | 04-15-2026 |
| Revenue: | $100,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.01 | Index: | N/A |
| Free Cash Flow: | -16256000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
10% Owner
Avg Cost/Share
$5.94
Shares
18,395
Total Value
$109,266.30
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$0.90
Shares
3,163
Total Value
$2,853.03
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$0.97
Shares
2,280
Total Value
$2,211.60
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$0.94
Shares
4,016
Total Value
$3,791.10
Owned After
113,304
SEC Form 4
10% Owner
Avg Cost/Share
$0.95
Shares
924
Total Value
$874.10
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$0.94
Shares
926
Total Value
$873.22
Owned After
113,304
SEC Form 4
10% Owner
Avg Cost/Share
$0.94
Shares
383
Total Value
$360.79
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 17, 2026 | Sell | $5.94 | 18,395 | $109,266.30 | 0 | |
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 14, 2026 | Sell | $0.90 | 3,163 | $2,853.03 | 0 | |
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 11, 2026 | Sell | $0.97 | 2,280 | $2,211.60 | 0 | |
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 10, 2026 | Buy | $0.94 | 4,016 | $3,791.10 | 113,304 | |
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 7, 2026 | Sell | $0.95 | 924 | $874.10 | 0 | |
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 6, 2026 | Buy | $0.94 | 926 | $873.22 | 113,304 | |
| HRT FINANCIAL LP | PFSA | 10% Owner | Aug 5, 2026 | Sell | $0.94 | 383 | $360.79 | 0 |
SEC 8-K filings with transcript text
Aug 20, 2026
false 0001859807
0001859807
2026-08-20 2026-08-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 20, 2026
(Exact name of registrant as specified in its charter)
Delaware
001-41177
86-3437271
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
626 Bancroft Way, Suite A
Berkeley, CA 94710
(Address of principal executive offices) (Zip Code)
(925) 997-6925
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§17 CFR 240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On August 20, 2026, Profusa, Inc. (the “Registrant”) issued a press release announcing certain financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
Exhibits.
Exhibit No.
Description
99.1
Press Release
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 20, 2026
By: /s/ Fred Knechtel
Name: Fred Knechtel
Title: Chief Financial Officer
2
See how PFSA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PFSA Profusa Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.